Advertisement

High oxidative stress in patients with stable coronary heart disease

      Abstract

      Oxidized low density lipoprotein (oxLDL) plays a pivotal role in the development of atherosclerosis. The aim of the study was to investigate the relationship between oxLDL and other oxidative stress biomarkers with stable coronary heart disease (CHD). We compared the degree of oxidative stress in patients with CHD and sex-matched healthy control subjects in a case-control study. The study included 64 male subjects: 32 patients with stable CHD and 32 normal control subjects. Levels of circulating oxLDL were measured by a monoclonal antibody 4E6-based competition ELISA. Comparison of oxidative stress marker levels between cases and controls, adjusted for age, revealed significantly higher plasma oxLDL levels (63.32±25.49 vs. 37.73±20.58 U/l, P=0.001), lower serum levels of autoantibodies against oxLDL (341.53±350.46 vs. 796.45±1034.2 mU/ml, P=0.021), higher activities of the antioxidant enzymes superoxide dismutase in erythrocytes (951±70.2 vs. 771.6±191.2 U/g, P=0.032) and glutathione peroxidase in whole blood (GSH-Px: 10 714.4±3705.4 vs. 5512.2±1498.1 U/l, P<0.001). The risk of having CHD was 20.6-fold greater (95% CI, 1.86–228.44, P=0.014) in the highest tertile of the oxLDL distribution than in the lowest, determined by logistic regression analysis on the combined study population after adjustment for age and other potential confounding factors. When the risk associated with GSH-Px levels was calculated, the odds ratio was 305.3 (95% CI, 5.07–18369.95, P=0.006) in the highest tertile compared with the lowest. Our results showed that an oxidative stress occurs in patients with CHD despite being clinically stable and under medical treatment. The combination of oxLDL levels and GSH-Px activity may be useful for the identification of patients with stable CHD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Witztum J.L.
        The oxidation hypothesis of atherosclerosis.
        Lancet. 1994; 344: 793-795
        • Gutteridge J.M.
        Lipid peroxidation and antioxidants as biomarkers of tissue damage.
        Clin. Chem. 1995; 41: 1819-1828
        • Aviram M.
        • Rosenblat M.
        • Billecke S.
        • et al.
        Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.
        Free Radic. Biol. Med. 1999; 26: 892-904
        • Steinberg D.
        • Parthasarathy S.
        • Carew T.E.
        • Khoo J.C.
        • Witztum J.L.
        Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.
        N. Engl. J. Med. 1989; 320: 915-924
        • Salonen J.T.
        • Yla-Herttuala S.
        • Yamamoto R.
        • et al.
        Autoantibody against oxidised LDL and progression of carotid atherosclerosis.
        Lancet. 1992; 339: 883-887
        • Hulthe J.
        • Wiklund O.
        • Hurt-Camejo E.
        • Bondjers G.
        Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2).
        Arterioscler. Thromb. Vasc. Biol. 2001; 21: 269-274
        • Holvoet P.
        • Vanhaecke J.
        • Janssens S.
        • Van de W.F.
        • Collen D.
        Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.
        Circulation. 1998; 98: 1487-1494
        • Ehara S.
        • Ueda M.
        • Naruko T.
        • et al.
        Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes.
        Circulation. 2001; 103: 1955-1960
        • Toshima S.
        • Hasegawa A.
        • Kurabayashi M.
        • et al.
        Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease.
        Arterioscler. Thromb. Vasc. Biol. 2000; 20: 2243-2247
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin. Chem. 1972; 18: 499-502
        • McCord J.M.
        • Fridovich I.
        Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein).
        J. Biol. Chem. 1969; 244: 6049-6055
        • Paglia D.E.
        • Valentine W.N.
        Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase.
        J. Lab. Clin. Med. 1967; 70: 158-169
        • Vasankari T.
        • Kujala U.
        • Heinonen O.
        • Kapanen J.
        • Ahotupa M.
        Measurement of serum lipid peroxidation during exercise using three different methods: diene conjugation, thiobarbituric acid reactive material and fluorescent chromolipids.
        Clin. Chim. Acta. 1995; 234: 63-69
        • Senti M.
        • Tomas M.
        • Marrugat J.
        • Elosua R.
        Paraoxonase1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs.
        Arterioscler. Thromb. Vasc. Biol. 2001; 21: 415-420
        • Zhou X.
        • Zhai X.
        • Ashraf M.
        Direct evidence that initial oxidative stress triggered by preconditioning contributes to second window of protection by endogenous antioxidant enzyme in myocytes.
        Circulation. 1996; 93: 1177-1184
        • Holvoet P.
        • Stassen J.M.
        • Van Cleemput J.
        • Collen D.
        • Vanhaecke J.
        Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease.
        Arterioscler. Thromb. Vasc. Biol. 1998; 18: 100-107
        • Holvoet P.
        • Mertens A.
        • Verhamme P.
        • et al.
        Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.
        Arterioscler. Thromb. Vasc. Biol. 2001; 21: 844-848
        • Rajman I.
        • Maxwell S.
        • Cramb R.
        • Kendall M.
        Particle size: the key to the atherogenic lipoprotein?.
        QJM. 1994; 87: 709-720
        • Regnstrom J.
        • Nilsson J.
        • Tornvall P.
        • Landou C.
        • Hamsten A.
        Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man.
        Lancet. 1992; 339: 1183-1186
        • Tornvall P.
        • Karpe F.
        • Carlson L.A.
        • Hamsten A.
        Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction.
        Atherosclerosis. 1991; 90: 67-80
        • Junjun W.
        • Yiyi Z.
        • Xiaozhuan L.
        • Daning C.
        The in vivo oxidized LDL to LDL-cholesterol ratio is correlated with lipid content of LDL.
        Atherosclerosis. 2000; 149: 217-218
        • Yla-Herttuala S.
        • Palinski W.
        • Butler S.W.
        • Picard S.
        • Steinberg D.
        • Witztum J.L.
        Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL.
        Arterioscler. Thromb. 1994; 14: 32-40
        • Palinski W.
        • Miller E.
        • Witztum J.L.
        Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis.
        Proc. Natl. Acad. Sci. USA. 1995; 92: 821-825
        • Bergmark C.
        • Wu R.
        • de Faire U.
        • Lefvert A.K.
        • Swedenborg J.
        Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL.
        Arterioscler. Thromb. Vasc. Biol. 1995; 15: 441-445
        • Lehtimaki T.
        • Lehtinen S.
        • Solakivi T.
        • et al.
        Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease.
        Arterioscler. Thromb. Vasc. Biol. 1999; 19: 23-27
        • Puurunen M.
        • Manttari M.
        • Manninen V.
        • et al.
        Antibody against oxidized low-density lipoprotein predicting myocardial infarction.
        Arch. Int. Med. 1994; 154: 2605-2609
        • Wu R.
        • de Faire U.
        • Lemne C.
        • Witztum J.L.
        • Frostegard J.
        Autoantibodies to oxLDL are decreased in individuals with borderline hypertension.
        Hypertension. 1999; 33: 53-59
        • Cherubini A.
        • Mecocci P.
        • Senin U.
        • Lowenthal D.T.
        • Barnert G.
        • Chionne F.
        Autoantibodies against oxidized low-density lipoproteins in older stroke patients.
        J. Am. Geriatr. Soc. 1997; 45: 125
        • Schumacher M.
        • Eber B.
        • Tatzber F.
        • et al.
        Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction.
        Free Radic. Biol. Med. 1995; 18: 1087-1091
        • Lopes-Virella M.F.
        • Virella G.
        • Orchard T.J.
        • et al.
        Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
        Clin. Immunol. 1999; 90: 165-172
        • Ahmed E.
        • Trifunovic J.
        • Stegmayr B.
        • Hallmans G.
        • Lefvert A.K.
        Autoantibodies against oxidatively modified LDL do not constitute a risk factor for stroke: a nested case-control study.
        Stroke. 1999; 30: 2541-2546
        • van de Vijver L.P.
        • Steyger R.
        • van Poppel G.
        • et al.
        Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls.
        Atherosclerosis. 1996; 122: 245-253
        • Shoji T.
        • Nishizawa Y.
        • Fukumoto M.
        • et al.
        Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects.
        Atherosclerosis. 2000; 148: 171-177
        • Hulthe J.
        • Wikstrand J.
        • Lidell A.
        • Wendelhag I.
        • Hansson G.K.
        • Wiklund O.
        Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia.
        Arterioscler. Thromb. Vasc. Biol. 1998; 18: 1203-1211